A trial is scheduled to start Monday in Little Rock, Ark., in which the state of Arkansas will try to prove that Johnson & Johnson's Janssen Pharmaceutica subsidiary illegally promoted the antipsychotic drug Risperdal for unapproved uses and did not sufficiently divulge negative side effects.
According to the Associated Press story, which is below, the two sides were negotiating a settlement, but talks ended Friday.
Sometimes, talks resume.
Several days after a similar trial began regarding similar allegations in Texas, J&J agreed to pay the state of Texas $158 million to stop the proceedings. The case began with whistleblower Allen Jones finding problems in Pennsylvania.
Risperdal litigation is pending in several states and the Justice Department is negotiating with J&J over federal charges.
Texas Medicaid chief Billy Millwee testified Thursday in Washington at a Senate Finance subcommittee hearing on the subject.
"When you shine a bright light on something, that's how you get it fixed," Millwee said.
Here is the AP story on the Arkansas case: